LATS1 and breast carcinoma: Ad-K8-nlsCre specifically targeted K8+ mammary luminal cells in a control tdTomato mouse (Supplementary Fig. 1j) and when injected into LATS1/2-floxed mice, 12 out of 19 mice developed overt mammary carcinomas over periods of 8–20 months after Cre delivery (Fig. 1i and Supplementary Fig. 1k).